£68.57B Market Cap.
GSK Market Cap. (MRY)
GSK Shares Outstanding (MRY)
GSK Assets (MRY)
Total Assets
£59.46B
Total Liabilities
£46.38B
Total Investments
£1.22B
GSK Income (MRY)
Revenue
£31.38B
Net Income
£2.58B
Operating Expense
£18.31B
GSK Cash Flow (MRY)
CF Operations
£6.55B
CF Investing
-£1.23B
CF Financing
-£4.73B
GSK Dividends (MRY)
Period | Dividends | Yield % | Growth % | Payout Ratio | Coverage Ratio |
|---|---|---|---|---|---|
2024 | $1.56 | 4.60% | 12.10% | 123.18% | 0.81 |
2023 | $1.39 | 3.70% | -27.77% | 57.11% | 1.75 |
2022 | $1.92 | 5.50% | -30.35% | 25.89% | 3.86 |
2021 | $2.76 | 5.00% | 7.31% | 125.96% | 0.79 |
2020 | $2.57 | 5.60% | - | 89.09% | 1.12 |
GSK Balance Sheet (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Total Assets | £59,463,000,000 (0.78%) | £59,005,000,000 (-1.90%) | £60,146,000,000 (-23.96%) | £79,103,000,000 (-1.65%) |
Assets Current | £16,997,000,000 (-8.83%) | £18,644,000,000 (-10.23%) | £20,769,000,000 (11.22%) | £18,674,000,000 (-7.77%) |
Assets Non-Current | £42,466,000,000 (5.22%) | £40,361,000,000 (2.50%) | £39,377,000,000 (-34.84%) | £60,429,000,000 (0.41%) |
Goodwill & Intangible Assets | £22,497,000,000 (4.25%) | £21,579,000,000 (1.01%) | £21,364,000,000 (-47.42%) | £40,631,000,000 (0.52%) |
Shareholders Equity | £13,671,000,000 (2.43%) | £13,347,000,000 (25.94%) | £10,598,000,000 (-29.60%) | £15,055,000,000 (3.21%) |
Property Plant & Equipment Net | £10,073,000,000 (1.17%) | £9,957,000,000 (3.50%) | £9,620,000,000 (-9.86%) | £10,672,000,000 (-3.03%) |
Cash & Equivalents | £3,870,000,000 (31.81%) | £2,936,000,000 (-21.14%) | £3,723,000,000 (-12.89%) | £4,274,000,000 (-32.07%) |
Accumulated Other Comprehensive Income | £0 (0%) | £0 (0%) | £0 (0%) | £0 (0%) |
Deferred Revenue | £0 (0%) | £0 (0%) | £0 (0%) | £0 (0%) |
Total Investments | £1,217,000,000 (-64.60%) | £3,438,000,000 (-39.63%) | £5,695,000,000 (150.33%) | £2,275,000,000 (-35.04%) |
Investments Current | £21,000,000 (-99.07%) | £2,246,000,000 (-45.93%) | £4,154,000,000 (6709.84%) | £61,000,000 (-21.79%) |
Investments Non-Current | £1,196,000,000 (0.34%) | £1,192,000,000 (-22.65%) | £1,541,000,000 (-30.40%) | £2,214,000,000 (-35.34%) |
Inventory | £5,669,000,000 (3.11%) | £5,498,000,000 (6.84%) | £5,146,000,000 (-11.02%) | £5,783,000,000 (-3.55%) |
Trade & Non-Trade Receivables | £6,836,000,000 (-7.43%) | £7,385,000,000 (4.71%) | £7,053,000,000 (-10.27%) | £7,860,000,000 (13.06%) |
Trade & Non-Trade Payables | £15,335,000,000 (-3.21%) | £15,844,000,000 (-2.58%) | £16,263,000,000 (-7.35%) | £17,554,000,000 (10.82%) |
Accumulated Retained Earnings (Deficit) | £7,796,000,000 (7.69%) | £7,239,000,000 (65.92%) | £4,363,000,000 (-45.08%) | £7,944,000,000 (17.60%) |
Tax Assets | £7,246,000,000 (12.83%) | £6,422,000,000 (5.92%) | £6,063,000,000 (6.29%) | £5,704,000,000 (15.05%) |
Tax Liabilities | £1,085,000,000 (22.46%) | £886,000,000 (-0.11%) | £887,000,000 (-79.01%) | £4,225,000,000 (-2.22%) |
Total Debt | £16,986,000,000 (-5.73%) | £18,018,000,000 (-14.15%) | £20,987,000,000 (-13.18%) | £24,173,000,000 (-10.97%) |
Debt Current | £2,349,000,000 (-16.49%) | £2,813,000,000 (-28.82%) | £3,952,000,000 (9.75%) | £3,601,000,000 (-3.33%) |
Debt Non-Current | £14,637,000,000 (-3.74%) | £15,205,000,000 (-10.74%) | £17,035,000,000 (-17.19%) | £20,572,000,000 (-12.18%) |
Total Liabilities | £46,377,000,000 (0.36%) | £46,210,000,000 (-7.67%) | £50,050,000,000 (-13.35%) | £57,761,000,000 (-3.12%) |
Liabilities Current | £21,697,000,000 (2.99%) | £21,068,000,000 (-7.64%) | £22,810,000,000 (-3.63%) | £23,670,000,000 (6.87%) |
Liabilities Non-Current | £24,680,000,000 (-1.84%) | £25,142,000,000 (-7.70%) | £27,240,000,000 (-20.10%) | £34,091,000,000 (-9.03%) |
GSK Income Statement (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Revenues | £31,376,000,000 (3.46%) | £30,328,000,000 (3.42%) | £29,324,000,000 (18.74%) | £24,696,000,000 (1.40%) |
Cost of Revenue | £9,048,000,000 (5.64%) | £8,565,000,000 (-10.35%) | £9,554,000,000 (17.04%) | £8,163,000,000 (2.95%) |
Selling General & Administrative Expense | £11,015,000,000 (17.37%) | £9,385,000,000 (12.10%) | £8,372,000,000 (18.42%) | £7,070,000,000 (-4.93%) |
Research & Development Expense | £6,401,000,000 (2.86%) | £6,223,000,000 (13.39%) | £5,488,000,000 (9.34%) | £5,019,000,000 (4.72%) |
Operating Expenses | £18,307,000,000 (21.90%) | £15,018,000,000 (12.60%) | £13,337,000,000 (9.54%) | £12,176,000,000 (16.56%) |
Interest Expense | £669,000,000 (-15.53%) | £792,000,000 (-9.90%) | £879,000,000 (14.30%) | £769,000,000 (-12.01%) |
Income Tax Expense | £526,000,000 (-30.42%) | £756,000,000 (6.93%) | £707,000,000 (751.81%) | £83,000,000 (23.88%) |
Net Loss Income from Discontinued Operations | £0 (0%) | £0 (0%) | -£10,700,000,000 (-577.22%) | -£1,580,000,000 (-22.96%) |
Consolidated Income | £2,951,000,000 (-44.40%) | £5,308,000,000 (-66.02%) | £15,621,000,000 (206.53%) | £5,096,000,000 (-20.23%) |
Net Income to Non-Controlling Interests | £376,000,000 (-1.05%) | £380,000,000 (-71.43%) | £1,330,000,000 (-6.47%) | £1,422,000,000 (11.27%) |
Net Income | £2,575,000,000 (-47.75%) | £4,928,000,000 (-67.05%) | £14,956,000,000 (241.07%) | £4,385,000,000 (-23.73%) |
Preferred Dividends Income Statement Impact | £0 (0%) | £0 (0%) | £0 (0%) | £0 (0%) |
Net Income Common Stock | £2,575,000,000 (-47.75%) | £4,928,000,000 (-67.05%) | £14,956,000,000 (241.07%) | £4,385,000,000 (-23.73%) |
Weighted Average Shares | £4,055,000,000 (0.00%) | £4,055,000,000 (0.62%) | £4,030,000,000 (0.59%) | £4,006,400,000 (0.37%) |
Weighted Average Shares Diluted | - | - | - | - |
Earning Before Interest & Taxes (EBIT) | £3,770,000,000 (-41.79%) | £6,476,000,000 (-60.85%) | £16,542,000,000 (215.87%) | £5,237,000,000 (-21.72%) |
Gross Profit | £22,328,000,000 (2.60%) | £21,763,000,000 (10.08%) | £19,770,000,000 (19.58%) | £16,533,000,000 (0.66%) |
Operating Income | £4,021,000,000 (-40.39%) | £6,745,000,000 (4.85%) | £6,433,000,000 (47.65%) | £4,357,000,000 (-27.13%) |
GSK Cash Flow Statement (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Net Cash Flow from Investing | -£1,229,000,000 (22.95%) | -£1,595,000,000 (81.82%) | -£8,772,000,000 (-393.64%) | -£1,777,000,000 (-182.23%) |
Net Cash Flow from Financing | -£4,726,000,000 (16.22%) | -£5,641,000,000 (-785.42%) | £823,000,000 (110.84%) | -£7,589,000,000 (25.10%) |
Net Cash Flow from Operations | £6,554,000,000 (-3.16%) | £6,768,000,000 (-8.58%) | £7,403,000,000 (-6.90%) | £7,952,000,000 (-5.79%) |
Net Cash Flow / Change in Cash & Cash Equivalents | £599,000,000 (0%) | £0 (0%) | -£546,000,000 (61.39%) | -£1,414,000,000 (-400.85%) |
Net Cash Flow - Business Acquisitions and Disposals | -£871,000,000 (38.10%) | -£1,407,000,000 (56.37%) | -£3,225,000,000 (-2194.16%) | £154,000,000 (541.67%) |
Net Cash Flow - Investment Acquisitions and Disposals | £2,290,000,000 (14.44%) | £2,001,000,000 (1984.38%) | £96,000,000 (65.52%) | £58,000,000 (-97.97%) |
Capital Expenditure | -£1,334,000,000 (-3.73%) | -£1,286,000,000 (-28.99%) | -£997,000,000 (-21.88%) | -£818,000,000 (12.98%) |
Issuance (Repayment) of Debt Securities | -£1,392,000,000 (45.77%) | -£2,567,000,000 (46.79%) | -£4,824,000,000 (-120.88%) | -£2,184,000,000 (48.20%) |
Issuance (Purchase) of Equity Shares | £20,000,000 (100.00%) | £10,000,000 (-60.00%) | £25,000,000 (19.05%) | £21,000,000 (-27.59%) |
Payment of Dividends & Other Cash Distributions | -£2,444,000,000 (-8.77%) | -£2,247,000,000 (35.19%) | -£3,467,000,000 (13.30%) | -£3,999,000,000 (-0.55%) |
Effect of Exchange Rate Changes on Cash | -£54,000,000 | - | £152,000,000 (624.14%) | -£29,000,000 (25.64%) |
Share Based Compensation | - | - | £0 (0%) | £0 (0%) |
Depreciation Amortization & Accretion | £2,985,000,000 (4.77%) | £2,849,000,000 (7.55%) | £2,649,000,000 (-2.18%) | £2,708,000,000 (0%) |
GSK Financial Metrics (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Gross Margin | 71.20% (-0.84%) | 71.80% (6.53%) | 67.40% (0.75%) | 66.90% (-0.74%) |
Profit Margin | 8.20% (-49.38%) | 16.20% (-68.24%) | 51.00% (186.52%) | 17.80% (-24.58%) |
EBITDA Margin | 21.50% (-29.97%) | 30.70% (-53.06%) | 65.40% (103.11%) | 32.20% (17.09%) |
Return on Average Equity (ROAE) | 18.40% (-52.45%) | 38.70% (-66.17%) | 114.40% (295.85%) | 28.90% (-30.19%) |
Return on Average Assets (ROAA) | 4.40% (-46.99%) | 8.30% (-58.50%) | 20.00% (257.14%) | 5.60% (-20.00%) |
Return on Sales (ROS) | 12.00% (-43.93%) | 21.40% (-62.06%) | 56.40% (166.04%) | 21.20% (-22.91%) |
Return on Invested Capital (ROIC) | 13.00% (-32.99%) | 19.40% (-51.74%) | 40.20% (187.14%) | 14.00% (-13.04%) |
Dividend Yield | 4.60% (24.32%) | 3.70% (-32.73%) | 5.50% (10.00%) | 5.00% (-10.71%) |
Price to Earnings Ratio (P/E) | 21.41 (77.81%) | 12.04 (206.54%) | 3.93 (-79.18%) | 18.86 (62.22%) |
Price to Sales Ratio (P/S) | 1.75 (-10.68%) | 1.96 (-2.35%) | 2 (-40.25%) | 3.35 (21.88%) |
Price to Book Ratio (P/B) | 4.01 (-9.76%) | 4.45 (-19.80%) | 5.54 (0.80%) | 5.5 (19.72%) |
Debt to Equity Ratio (D/E) | 3.39 (-2.02%) | 3.46 (-26.70%) | 4.72 (23.09%) | 3.84 (-6.12%) |
Earnings Per Share (EPS) | 1.26 (-48.03%) | 2.43 (-67.26%) | 7.43 (238.87%) | 2.19 (-24.10%) |
Sales Per Share (SPS) | 19.34 (2.16%) | 18.93 (7.99%) | 17.53 (6.67%) | 16.44 (-1.66%) |
Free Cash Flow Per Share (FCFPS) | 2.58 (-4.77%) | 2.7 (-14.94%) | 3.18 (-10.73%) | 3.56 (-5.24%) |
Book Value Per Share (BVPS) | 6.74 (2.43%) | 6.58 (25.15%) | 5.26 (-30.01%) | 7.51 (2.82%) |
Tangible Assets Book Value Per Share (TABVPS) | 18.23 (-1.23%) | 18.46 (-4.09%) | 19.25 (0.22%) | 19.2 (-4.20%) |
Enterprise Value Over EBIT (EV/EBIT) | 18 (50.00%) | 12 (140.00%) | 5 (-75.00%) | 20 (53.85%) |
Enterprise Value Over EBITDA (EV/EBITDA) | 10.1 (23.32%) | 8.19 (105.11%) | 3.99 (-70.00%) | 13.31 (-1.12%) |
Asset Turnover | 0.54 (5.10%) | 0.51 (30.10%) | 0.39 (24.05%) | 0.32 (7.12%) |
Current Ratio | 0.78 (-11.53%) | 0.89 (-2.85%) | 0.91 (15.46%) | 0.79 (-13.68%) |
Dividends | £1.56 (12.10%) | £1.39 (-27.77%) | £1.92 (-30.35%) | £2.76 (7.31%) |
Free Cash Flow (FCF) | £5,220,000,000 (-4.78%) | £5,482,000,000 (-14.42%) | £6,406,000,000 (-10.20%) | £7,134,000,000 (-4.89%) |
Enterprise Value (EV) | £85,280,439,610 (-11.79%) | £96,674,515,854 (4.71%) | £92,329,193,023 (-34.51%) | £140,980,882,759 (14.30%) |
Earnings Before Tax (EBT) | £3,101,000,000 (-45.44%) | £5,684,000,000 (-63.71%) | £15,663,000,000 (250.56%) | £4,468,000,000 (-23.18%) |
Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) | £6,755,000,000 (-27.56%) | £9,325,000,000 (-51.41%) | £19,191,000,000 (141.55%) | £7,945,000,000 (18.76%) |
Invested Capital | £28,385,000,000 (-9.72%) | £31,440,000,000 (-5.40%) | £33,236,000,000 (-4.22%) | £34,701,000,000 (-10.38%) |
Working Capital | -£4,700,000,000 (-93.89%) | -£2,424,000,000 (-18.77%) | -£2,041,000,000 (59.15%) | -£4,996,000,000 (-162.81%) |
Tangible Asset Value | £36,966,000,000 (-1.23%) | £37,426,000,000 (-3.50%) | £38,782,000,000 (0.81%) | £38,472,000,000 (-3.84%) |
Market Capitalization | £68,570,050,000 (-8.74%) | £75,139,150,000 (6.12%) | £70,807,100,000 (-35.88%) | £110,426,400,000 (20.28%) |
Average Equity | £13,972,750,000 (9.61%) | £12,747,750,000 (-2.51%) | £13,076,250,000 (-13.86%) | £15,180,750,000 (9.29%) |
Average Assets | £58,522,250,000 (-1.61%) | £59,481,000,000 (-20.48%) | £74,798,250,000 (-4.38%) | £78,220,500,000 (-5.30%) |
Invested Capital Average | £29,105,750,000 (-12.88%) | £33,410,250,000 (-18.76%) | £41,124,750,000 (10.00%) | £37,386,000,000 (-9.78%) |
Shares | 4,055,000,000 (0.00%) | 4,055,000,000 (0.62%) | 4,030,000,000 (0.59%) | 4,006,400,000 (0.37%) |
